Research Article

C16-Ceramide Analog Combined with Pc 4 Photodynamic Therapy Evokes Enhanced Total Ceramide Accumulation, Promotion of DEVDase Activation in the Absence of Apoptosis, and Augmented Overall Cell Killing

Duska Separovic, 1, 2 Ziad H. Saad, 1 Ethan A. Edwin, 1 Jacek Bielawski, 3 Jason S. Pierce, 3 Eric Van Buren, 2 and Alicja Bielawska 3

1 Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI 48201, USA
2 Karmanos Cancer Institute, 4100 John R, Wayne State University, Detroit, MI 48201, USA
3 Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425, USA

Correspondence should be addressed to Duska Separovic, dseparovic@wayne.edu

Received 2 August 2010; Accepted 24 September 2010

Academic Editor: Philip W. Wertz

Because of the failure of single modality approaches, combination therapy for cancer treatment is a promising alternative. Sphingolipid analogs, with or without anticancer drugs, can improve tumor response. C16-pyridinium ceramide analog LCL30, was used in combination with photodynamic therapy (PDT), an anticancer treatment modality, to test the hypothesis that the combined treatment will trigger changes in the sphingolipid profile and promote cell death. Using SCCVII mouse squamous carcinoma cells, and the silicone phthalocyanine Pc 4 for PDT, we showed that combining PDT with LCL30 (PDT/LCL30) was more effective than individual treatments in raising global ceramide levels, as well as in reducing dihydrosphingosine levels. Unlike LCL30, PDT, alone or combined, increased total dihydroceramide levels. Sphingosine levels were unaffected by LCL30, but were abolished after PDT or the combination. LCL30-triggered rise in sphingosine-1-phosphate was reversed post-PDT or the combination. DEVDase activation was evoked after PDT or LCL30, and was promoted post-PDT/LCL30. Neither mitochondrial depolarization nor apoptosis were observed after any of the treatments. Notably, treatment with the combination resulted in augmented overall cell killing. Our data demonstrate that treatment with PDT/LCL30 leads to enhanced global ceramide levels and DEVDase activation in the absence of apoptosis, and promotion of total cell killing.

1. Introduction

Sphingolipids (SLs) are structural components of cell membranes, as well as important players in a variety of biological functions [1]. Ceramide and sphingosine have been associated with proapoptotic and tumor-suppressor functions, whereas sphingosine-1-phosphate (SIP) appears to have prosurvival and tumor-promoting effects [2, 3].

Targeting SLs has been used for new anticancer drug design [4, 5]. Exposure of chemoresistant MCF-7 cells to short-chain ceramide analogs, for example, 4,6-dienece-ramide, leads to the accumulation of endogenous ceramide, apoptosis, and inhibition of clonogenic survival [6–8]. Cationic ceramide conjugates with pyridinium salts (CCPS analogs) were synthesized that target mitochondria and with improved physicochemical properties [9]. Mitochondrial targeting is important for cancer treatment because cancer cells tend to have mitochondria with more negative mitochondrial membrane potential [10]. These novel ceramide analogs (C2-C16 CCPS) are potent anticancer agents, alone or in combination with standard chemotherapy [9, 11–14]. Exposure of MCF-7 cells to the short-chain homolog LCL29
example, we have shown in Jurkat cells that silencing of ceramide-utilizing enzyme sphingomyelin synthase leads to enhanced ceramide and dihydroceramide accumulation with concomitant promotion of apoptosis [32]. Combining PDT with the anticancer LCL30 is expected to promote tumor response to PDT and, therefore, improve clinical PDT.

2. Materials and Methods

2.1. Materials. D-erythro-2-N-[16′-(1′″-pyridinium)-hexadecanoyl]-sphingosine bromide (LCL30) was synthesized in the Lipidomics Shared Resource of the Medical University of South Carolina [9]. The phthalocyanine photosensitizer Pc 4, HOSiPCOSi(CH3)2(CH2)3N(CH3)2, was supplied by Dr. Malcolm E. Kenney (Department of Chemistry, Case Western Reserve University). RPMI medium and serum were from Invitrogen and Hyclone, respectively.

2.2. Cell Culture and Treatments. SCCVII cells were grown in RPMI medium (Invitrogen) containing 10% fetal bovine serum (Hyclone) 100 units/mL penicillin and 100 μg/mL streptomycin. Cells were maintained at 37°C in a 5% CO2 atmosphere and were treated in the growth medium. For PDT experiments, after overnight incubation with Pc 4 at 37°C, cells were irradiated with red light (2 milliwatts/cm2; λ max ~ 670 nm) using a light-emitting diode array light source (EFOS) at the fluence of 200 mJ/cm2 at room temperature. Following PDT, cells were incubated at 37°C for 2 hours. For the combination, LCL30 (1 μM) was added to Pc 4-pretreated cell cultures 2 hours prior to irradiation. For cells treated with LCL30 alone, the incubation time was 4 hours. Following treatments, cells were collected on ice and processed for various analyses. For MS analysis, cells were washed twice with cold phosphate-buffered saline (PBS), resuspended in the mixture of ethyl acetate/methanol (1:1, v/v), dried under nitrogen, and shipped overnight on dry ice to the Lipidomics Shared Resource (Charleston, SC) for further processing.

2.3. Electrospray Ionization/Double MS Analysis. Following extraction, SLs were separated by high-performance liquid chromatography, introduced to electrospray ionization source, and then analyzed by double MS using TSQ 7000 triple quadrupole mass spectrometer (Thermo-Fisher Scientific) as described previously [32].

2.4. Mitochondrial Membrane Depolarization Measurement. As we showed previously [36], the lipophilic cationic dye JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetrathylbenzimidazolylcarbocyanine iodide; Molecular Probes) was used to determine mitochondrial membrane potential by flow cytometry. JC-1 forms aggregates in normal mitochondria with a high negative membrane potential that emit a red fluorescence (590 nm). In mitochondria with low membrane potential (depolarized), the dye forms monomers in the cytosol that emit a green fluorescence (527 nm) [37]. Following treatments, cells were collected, washed in PBS, resuspended in JC-1-containing medium (2 μM final

\[ \text{L-Serine + palmitoyl CoA} \rightarrow \text{Dihydrophosphingosine} \rightarrow \text{Dihydroceramide} \rightarrow \text{Ceramide} \rightarrow \text{Sphingosine} \rightarrow \text{Sphingosine-1-phosphate} \]

**Figure 1:** De novo ceramide metabolism.
Figure 2: LCL30 is taken up by SCCVII cells treated with LCL30 or (PDT+LCL30). (PDT+LCL30): following overnight exposure to Pc 4 (250 nM), cells were treated with LCL30 (1 μM) for 2 hours, irradiated with red light (200 mJ/cm²), and incubated for additional 2 hours. For cells treated with LCL30 alone, the incubation time was 4 hours. Following incubations, cells were collected and processed for MS. The LCL30 levels are expressed as actual values (pmol/mg) and are shown as average ± SEM from four independent determinations.

concentration), and incubated at 37°C for 15 minutes. The samples were centrifuged, resuspended in growth medium, and analyzed by flow cytometry using BD LSR II flow cytometer (BD Biosciences). As a positive control for mitochondrial depolarization and apoptosis, cells were treated with camptothecin (5 μM) overnight and processed for flow cytometry.

2.5. Apoptosis Detection. As we showed previously [38], to detect apoptosis, the exposure of phosphatidylserine in the outer leaflet of the cell membrane was measured using Annexin V, a protein which binds with high affinity to negatively charged phosphatidylserine in the presence of calcium. As apoptosis progresses, cell membrane integrity is lost, and this can be detected using DNA-binding fluorescent dye propidium iodide (PI, red fluorescence). By attaching Annexin V to the fluorescein isothiocyanate (FITC; green fluorescence), one can discriminate between intact cells (Annexin V negative, PI negative), early apoptotic (Annexin V positive, PI negative), and late apoptotic or necrotic cells (Annexin V positive, PI positive). The kit was purchased from BD Pharmingen and the flow cytometry protocol was followed, as described by the manufacturer.

2.6. DEVDase (Caspase-3-Like) Activity Assay. As described previously [34], the activity of the apoptotic marker DEVDase was determined in cytosol by an assay based on the enzyme's ability to cleave the fluorogenic derivative 7-amino-4-methylcoumarin (AMC; Biomol) of the tetrapeptide substrate N-acetyl-Asp-Glu-Val-Asp (DEVD). The released fluorescence of the cleaved DEVD substrate was measured in F-2500 Hitachi spectrofluorometer (380 nm excitation and 460 nm emission).

2.7. Clonogenic Assay. Cell viability was assessed using clonogenic assay. The protocol that we described previously [38, 39] was modified using preplating approach, which allows keeping the treatments in the medium during colony formation. Following addition of Pc 4 or LCL30, cells were seeded in the growth medium, preincubated overnight, and irradiated. After eight days of growth at 37°C, colonies (≥50 cells) were stained with crystal violet (0.1%) and counted. Plating efficiency was 76% (n = 81).

2.8. Statistical Analysis. Statistical differences were determined using Student’s t-test (P < .05).

3. Results and Discussion

3.1. LCL30 Is Taken up by SCCVII Cells. We showed rapid uptake of LCL30 by MCF-7 cells [9]. Here, we determined uptake of LCL30 by SCCVII cells using MS. Following a four-hour incubation of cells with LCL30 (1 μM), cellular levels of LCL30 were 260 ± 4 pmol/10⁶ cells, corresponding...
3.2. PDT/LCL30 Is More Effective Than Individual Treatments in Raising Global Levels of Ceramides. We have already demonstrated that PDT has signature effects on the SL profile in cancer cell lines and in vivo [21, 32, 39]. We [9] and others [14] have also shown that LCL30 triggers changes in endogenous ceramides and S1P in human cancer cell lines. In the present study, we used MS to determine the effects of the combination, as well as of the individual treatments, on the SL profile in SCCVII cells. The effects of treatments on ceramides, individual and global, are shown in Table 1 and Figure 3(a). Only C20:1-ceramide was elevated after all treatments. Globally, there was 1.29- and 1.47-fold increase in ceramide levels after PDT and PDT/LCL30, respectively. LCL30 had no effect on total ceramides. The differences between individual treatments, LCL30 or PDT, and the combination, as well as between individual treatments themselves, were significant (P < .05).

The effects of treatments on the levels of dihydroceramides (DHceramides), individual and global, are depicted in Table 1 and Figure 3(b). Maximal increases were observed for C22- and C22:1-DHceramide after PDT and PDT/LCL30, respectively. There was no significant effect of LCL30 on total DHceramides. In contrast, PDT increased total DHceramides 1.48-fold, and the effect was maintained after the combination.
Figure 4: PDT, with or without LCL30, has no effect on mitochondrial membrane potential or apoptosis. Following incubations, cells were collected and processed for flow cytometry. JC-1 and Annexin V/PI staining were used to detect mitochondrial membrane potential (a) and apoptosis (b), respectively. See Section 2 for other details. (a) Percentage of cells with depolarized mitochondria is shown in lower right dot plot. (b) Percentage of Annexin V (+)/PI (−) and Annexin V (+)/PI (+) is shown in lower right and upper right dot plot, respectively. The representative data for PDT, with or without LCL30, from two independent experiments are shown.
DEVDase (fold change)

Figure 5: DEVDase activation is enhanced after (PDT+LCL30).
Following incubations (see Figure 2 legend), cells were collected, cell lysates were prepared, and DEVDase activity was measured using DEVD-AMC as the fluorogenic substrate. The data are expressed as fold changes, that is, ratios of treated versus untreated controls and are shown as average ± SEM from four to six independent determinations. The significance (P < .05) is shown by an asterisk indicating significant difference between an individual treatment, LCL30 or PDT, and the combination (PDT+LCL30).

The effects of treatments on other SLs are shown in Table 1 and Figure 3(c). The levels of dihydrosphingosine (DHsphingosine), a metabolic precursor of DHceramide, were reduced by 29, 41, and 75% after LCL30, PDT, and PDT/LCL30, respectively. The differences between treatments were significant (P < .05). Thus, PDT/LCL30 was more effective than individual treatments in reducing DHsphingosine levels. Sphingosine levels were abolished after PDT or the combination. LCL30 had no effect on sphingosine accumulation. In contrast, LCL30 triggered a marked 1.63-fold rise in S1P levels. PDT reduced S1P levels by 86%, and in combination with LCL30, by 44%.

3.3. PDT, with or without LCL30, Has No Effect on Mitochondrial Membrane Potential. We have shown that PDT combined with C16-ceramide enhances mitochondrial depolarization in Jurkat cells undergoing apoptosis [36]. Here, we tested whether PDT/LCL30 triggers the collapse of mitochondrial potential in SCCVII cells. As depicted in Figure 4(a), neither individual treatments nor the combination had any effect on mitochondrial membrane potential. In contrast, LCL30 triggered a marked 1.63-fold rise in S1P levels. PDT reduced S1P levels by 86%, and in combination with LCL30, by 44%.

3.4. PDT, with or without LCL30, Has No Effect on Apoptosis. PDT is a potent apoptotic inducer [40]. Surprisingly, in the presence of PDT, with or without LCL30, no apoptosis was detected in SCCVII cells using either Annexin V/PI staining (Figure 4(b)) or TUNEL assay (not shown). However, overnight treatment with camptothecin (5 μM) led to the appearance of 9% and 75% cells that were Annexin V (+)/PI (−) and Annexin V (+)/PI (+), respectively. Thus, unlike other treatments, camptothecin triggers early and late apoptosis/necrosis.

3.5. PDT/LCL30 Enhances DEVDase Activation. Although LCL30 was reported not to induce apoptosis [14], PDT is an effective apoptotic inducer [41]. We used DEVDase assay to assess the activity of caspase-3 as an apoptotic marker.
DEVDDase was activated 1.47- and 1.95-fold after LCL30 and PDT, respectively (Figure 5). After treatment of SCCVII cells with the combination, a 5.68-fold increase in DEVDDase activity was recorded. Therefore, the combined treatment augments the enzyme activity.

Previously, we showed that enhanced ceramide accumulation is associated with increased activation of DEVDDase after PDT [32, 35]. We also showed that DEVDDase activation is accompanied by mitochondrial depolarization and/or apoptosis post-PDT [33–36, 42, 43]. The present study shows DEVDDase activation in the absence of mitochondrial depolarization and apoptosis after PDT, with or without LCL30. Caspases, including caspase-3, have been associated with nonapoptotic functions, for example, survival [44–46]. Curiously, there was positive correlation between DEVDDase activation and the levels of prosurvival SIP after LCL30. In addition, there was negative correlation between the proapoptotic DHspingosine [33] and DEVDDase activation. The levels of proapoptotic sphingosine [47] were abolished after PDT or the combination with concomitant activation of DEVDDase. The role of DEVDDase activation in the absence of apoptosis in response to PDT, with or without LCL30, remains to be established.

3.6. PDT/LCL30 Augments Cell Killing. To determine the effect of LCL30 on overall cell killing, clonogenic assay was employed. As shown in Figure 6(a), treatment of SCCVII cells with 0.1, 1 and 5 μM LCL30 led to 7.8, 21.5 and 97.7% cell killing, respectively. The differences between each dose were significant (P < .05), supporting a dose-dependent cell killing after LCL30.

To test for potential enhancement of cell killing by the combination, LDs < 30 were chosen for each treatment. When SCCVII cells were treated with LCL30 (1 μM) and PDT (250 nM Pc 4 + 200 ml/cm²), 69.8% of the overall cell killing was observed (Figure 6(b)). The combination led to cell killing that was greater than that by each treatment alone (P < .05).

Taken together, the present study demonstrates for the first time that (i) LCL30 is taken up by SCCVII cells; (ii) cellular total ceramides are enhanced after PDT/LCL30; (iii) the activity of DEVDDase is upregulated in the absence of mitochondrial depolarization and apoptosis post-PDT/LCL30; (iv) total cell killing is augmented after the combination. Our findings warrant the use of other apoptotic markers besides DEVDDase to verify the triggering of apoptosis, and in vivo testing of PDT/LCL30 in view of translational potential of the combination.

Acknowledgments

This work was supported by U.S. Public Health Service Grant no. R01 CA77475 from the National Cancer Institute, National Institutes of Health. The MS-related work was done at the Lipidomics Shared Resource (Medical University of South Carolina, Charleston, SC), a facility supported by the U.S. Public Health Service Grant no. C06 RR018823 from the Extramural Research Facilities Program, National Center for Research Resources.

References

[1] Y. A. Hannun and L. M. Obeid, "Principles of bioactive lipid signalling: lessons from sphingolipids," Nature Reviews Molecular Cell Biology, vol. 9, no. 2, pp. 139–150, 2008.
[2] B. Ogretmen and Y. A. Hannun, "Biologically active sphingolipids in cancer pathogenesis and treatment," Nature Reviews Cancer, vol. 4, no. 8, pp. 604–616, 2004.
[3] N. J. Pyne and S. Pyne, "Sphingosine 1-phosphate and cancer," Nature Reviews Cancer, vol. 10, no. 7, pp. 489–503, 2010.
[4] T. E. Fox, C. M. Finnegan, R. Blumenthal, and M. Kester, "The clinical potential of sphingolipid-based therapeutics," Cellular and Molecular Life Sciences, vol. 63, no. 9, pp. 1017–1023, 2006.
[5] Y. H. Zeidan and Y. A. Hannun, "Translational aspects of sphingolipid metabolism," Trends in Molecular Medicine, vol. 13, no. 8, pp. 327–336, 2007.
[6] A. P. Struckhoff, R. Bittman, M. E. Burow et al., "Novel ceramide analogs as potential chemotherapeutic agents in breast cancer," Journal of Pharmacology and Experimental Therapeutics, vol. 309, no. 2, pp. 523–532, 2004.
[7] J. W. Antoon, J. Liu, M. M. Gestaut, M. E. Burow, B. S. Beckman, and M. Foroozesh, "Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells," Journal of Medicinal Chemistry, vol. 52, no. 18, pp. 5748–5752, 2009.
[8] J. Liu, J. W. Antoon, A. Ponnappakam, B. S. Beckman, and M. Foroozesh, "Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylidenamino)-3-hydroxy-N-tetradecylpropanamides," Bioorganic and Medicinal Chemistry, vol. 18, no. 14, pp. 5316–5322, 2010.
[9] Z. M. Szulc, J. Bielawski, H. Gracz et al., "Tailoring structure-function and targeting properties of ceramides by site-specific cationization," Bioorganic and Medicinal Chemistry, vol. 14, no. 21, pp. 7083–7104, 2006.
[10] L. B. Chen, "Mitochondrial membrane potential in living cells," Annual Review of Cell Biology, vol. 4, pp. 155–181, 1988.
[11] M. I. Rossi, K. Sundararaj, S. Koybasi et al., "Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells," Otolaryngology, vol. 132, no. 1, pp. 55–62, 2005.
[12] C. E. Senkal, S. Ponnumsamy, M. J. Rossi et al., "Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo," Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 3, pp. 1188–1199, 2006.
[13] D. Dindo, F. Dahm, Z. Szulc et al., "Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells," Molecular Cancer Therapeutics, vol. 5, no. 6, pp. 1520–1529, 2006.
[14] F. Dahm, A. Bielawska, A. Nocito et al., "Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice," British Journal of Cancer, vol. 98, no. 1, pp. 98–105, 2008.
[15] S. A. Novgorodov, Z. M. Szulc, C. Luberto et al., "Positively charged ceramide is a potent inducer of mitochondrial permeabilization," Journal of Biological Chemistry, vol. 280, no. 16, pp. 16096–16105, 2005.
[16] T. J. Dougherty, C. J. Gomer, B. W. Henderson et al., "Photodynamic therapy," Journal of the National Cancer Institute, vol. 90, no. 12, pp. 889–905, 1998.

Molecular Cell Biology
Nature Reviews Cancer
Molecular Cell
Nature Reviews Cancer
Trends in Molecular Medicine
British Journal of Cancer
Molecular Cancer Therapeutics
Journal of Pharmacology and Experimental Therapeutics
T O R T O C K S E N K A , S . P O N N U S A M Y , M . J . R O S S I E T A L . , " P O T E N T
S. Beckman, and M. Foroozesh, "Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells," Journal of Medicinal Chemistry, vol. 52, no. 18, pp. 5748–5752, 2009.
L. B. Chen, "Mitochondrial membrane potential in living cells," Annual Review of Cell Biology, vol. 4, pp. 155–181, 1988.
M. I. Rossi, K. Sundararaj, S. Koybasi et al., "Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells," Otolaryngology, vol. 132, no. 1, pp. 55–62, 2005.
C. E. Senkal, S. Ponnumsamy, M. J. Rossi et al., "Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo," Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 3, pp. 1188–1199, 2006.
D. Dindo, F. Dahm, Z. Szulc et al., "Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells," Molecular Cancer Therapeutics, vol. 5, no. 6, pp. 1520–1529, 2006.
F. Dahm, A. Bielawska, A. Nocito et al., "Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice," British Journal of Cancer, vol. 98, no. 1, pp. 98–105, 2008.
S. A. Novgorodov, Z. M. Szulc, C. Luberto et al., "Positively charged ceramide is a potent inducer of mitochondrial permeabilization," Journal of Biological Chemistry, vol. 280, no. 16, pp. 16096–16105, 2005.
T. J. Dougherty, C. J. Gomer, B. W. Henderson et al., "Photodynamic therapy," Journal of the National Cancer Institute, vol. 90, no. 12, pp. 889–905, 1998.
[17] A. P. Castano, P. Mroz, and M. R. Hamblin, “Photodynamic therapy and anti-tumour immunity,” Nature Reviews Cancer, vol. 6, no. 7, pp. 535–545, 2006.

[18] J. J. Wilson, H. Jones, M. Burock et al., “Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcormatosis,” International Journal of Oncology, vol. 24, no. 3, pp. 711–717, 2004.

[19] L. E. Rhodes, M. De Rie, Y. Enström et al., “Photodynamic therapy using topical methyl aminoenceullinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial,” Archives of Dermatology, vol. 140, no. 1, pp. 17–23, 2004.

[20] A. Bielawska, J. Bielawski, Z. M. Szulc et al., “Novel analogs of d-e-MAPP and B13—part 2: signature effects on bioactive sphingolipids,” Bioorganic and Medicinal Chemistry, vol. 16, no. 2, pp. 1032–1045, 2008.

[21] D. Separovic, J. Bielawski, J. S. Pierce et al., “Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCI29. Evidence from mouse squamous cell carcinomas,” British Journal of Cancer, vol. 100, no. 4, pp. 626–632, 2009.

[22] D. Khurana, E. A. Martin, J. L. Kasperbauer et al., “Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy,” Head and Neck, vol. 23, no. 10, pp. 899–906, 2001.

[23] C. Y. Anderson, K. Freye, K. A. Tubing et al., “A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice,” Photochemistry and Photobiology, vol. 67, no. 3, pp. 332–336, 1998.

[24] M. R. Detty, S. L. Gibson, and S. J. Wagner, “Current clinical and preclinical photosensitizers for use in photodynamic therapy,” Journal of Medicinal Chemistry, vol. 47, no. 16, pp. 3897–3915, 2004.

[25] R. Bose, M. Verheji, A. Harmovitz-Friedman, K. Scotto, Z. Fuks, and R. Kolesnik, “Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals,” Cell, vol. 82, no. 3, pp. 405–414, 1995.

[26] A. G. Charles, T.-Y. Han, Y. T. Liu, N. Hansen, A. E. Giuliano, and M. C. Cabot, “Taxol-induced ceramide generation and apoptosis in human breast cancer cells,” Cancer Chemotherapy and Pharmacology, vol. 47, no. 5, pp. 444–450, 2001.

[27] D. K. Perry, J. Carton, A. K. Shah, F. Meredith, D. J. Uhlinger, and Y. A. Hannun, “Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis,” Journal of Biological Chemistry, vol. 275, no. 12, pp. 9078–9084, 2000.

[28] C. E. Senkal, S. Ponnusamy, M. J. Rossi et al., “Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas,” Molecular Cancer Therapeutics, vol. 6, no. 2, pp. 712–722, 2007.

[29] J. Min, A. Mesika, M. Sivarguru et al., “(Dihydro)ceramide synthase 1-regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1,” Molecular Cancer Research, vol. 5, no. 8, pp. 801–812, 2007.

[30] H. Wang, B. J. Maurer, Y.-Y. Liu et al., “N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylphosphosine to enhance cancer cell killing,” Molecular Cancer Therapeutics, vol. 7, no. 9, pp. 2967–2976, 2008.

[31] D. Separovic, K. Hanada, M. Y. Maitah et al., “Sphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamage,” Biochemical and Biophysical Research Communications, vol. 358, no. 1, pp. 196–202, 2007.

[32] D. Separovic, L. Semaan, A. L. Tarca et al., “Suppression of sphingomyelin synthase 1 by small interference RNA is associated with enhanced ceramide production and apoptosis after photodamage,” Experimental Cell Research, vol. 314, no. 8, pp. 1860–1868, 2008.

[33] B. Wispriyono, E. M. Schmelz, H. Pelayo, K. Hanada, and D. Separovic, “A role for the de novo sphingolipids in apoptosis of photosensitized cells,” Experimental Cell Research, vol. 279, no. 1, pp. 153–165, 2002.

[34] V. Dolgachev, M. S. Faroqui, O. I. Kulaeva et al., “De novo ceramide accumulation due to inhibition of its conversion to complex sphingolipids in apoptotic photosensitized cells,” Journal of Biological Chemistry, vol. 279, no. 22, pp. 23238–23249, 2004.

[35] V. Dolgachev, L. W. Oberley, T.-T. Huang et al., “A role for manganese superoxide dismutase in apoptosis after photosensitization,” Biochemical and Biophysical Research Communications, vol. 332, no. 2, pp. 411–417, 2005.

[36] V. Dolgachev, B. Nagy, B. Taffe, K. Hanada, and D. Separovic, “Reactive oxygen species generation is independent of de novo sphingolipids in apoptotic photosensitized cells,” Experimental Cell Research, vol. 288, no. 2, pp. 425–436, 2003.

[37] A. Cossarizza, M. Baccarani-Contri, G. Kalashnikova, and C. Franceschi, “A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,6′,6′,6′′-tetrachloro-1′,3′,3′′-tetraethylbenzimidazolocarbocyanine iodide (JC-1),” Biochemical and Biophysical Research Communications, vol. 197, no. 1, pp. 40–45, 1993.

[38] D. Separovic, K. J. Mann, and N. L. Oleinick, “Association of ceramide accumulation with photodynamic treatment-induced cell death,” Photochemistry and Photobiology, vol. 68, no. 1, pp. 101–109, 1998.

[39] D. Separovic, A. Kelekar, A. K. Nayak et al., “Increased ceramide accumulation correlates with downregulation of the autophagy protein ATG-7 in MCF-7 cells sensitized to photodamage,” Archives of Biochemistry and Biophysics, vol. 494, no. 1, pp. 101–105, 2010.

[40] N. Oleinick, R. Morris, and A.-L. Nieminen, “Photodynamic therapy-induced apoptosis,” in Apoptosis, Senescence, and Cancer, pp. 557–578, 2007.

[41] N. L. Oleinick, R. L. Morris, and I. Belichenko, “The role of apoptosis in response to photodynamic therapy: what, where, why, and how,” Photochemical and Photobiological Sciences, vol. 1, no. 1, pp. 1–21, 2002.

[42] B. Nagy, S.-M. Chiu, and D. Separovic, “Fumonisin B1 does not prevent apoptosis in A431 human epidermoid carcinoma cells after photosensitization with a silicon phthalocyanine,” Journal of Photochemistry and Photobiology B, vol. 57, no. 2–3, pp. 132–141, 2000.

[43] B. Nagy, W.-C. Yeh, T. W. Mak, S.-M. Chiu, and D. Separovic, “FADD null mouse embryonic fibroblasts undergo apoptosis after photosensitization with the silicon phthalocyanine Pc 4,” Archives of Biochemistry and Biophysics, vol. 385, no. 1, pp. 194–202, 2001.
[44] C. Miossec, V. Dutilleul, F. Fassy, and A. Diu-Hercend, “Evidence for CPP32 activation in the absence of apoptosis during T lymphocyte stimulation,” *Journal of Biological Chemistry*, vol. 272, no. 21, pp. 13459–13462, 1997.

[45] M. Pederzoli, C. Kantari, V. Gausson, S. Moriceau, and V. Witko-Sarsat, “Proteinase-3 induces procaspase-3 activation in the absence of apoptosis: potential role of this compartmentalized activation of membrane-associated procaspase-3 in neutrophils,” *Journal of Immunology*, vol. 174, no. 10, pp. 6381–6390, 2005.

[46] C. Schwerk and K. Schulze-Osthoff, “Non-apoptotic functions of caspases in cellular proliferation and differentiation,” *Biochemical Pharmacology*, vol. 66, no. 8, pp. 1453–1458, 2003.

[47] T. A. Taha, T. D. Mullen, and L. M. Obeid, “A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death,” *Biochimica et Biophysica Acta*, vol. 1758, no. 12, pp. 2027–2036, 2006.